London Cartilage Clinic
Explore expert articles on cartilage care, regenerative treatments, and practical recovery advice from our specialist team.
Only 3–8% of ChondroFiller-treated patients require further surgery over three to five years, compared with 41% for microfracture—because the collagen scaffold recruits the patient's own repair tissue, which persists after the scaffold resorbs.
An injectable collagen scaffold that recruits the joint's own cells to repair cartilage damage, ChondroFiller offers structural regeneration earlier in the treatment pathway than knee replacement. Evidence from appropriately selected candidates shows 70–85% achieve meaningful symptom relief within three to five years.
ChondroFiller is an injectable collagen scaffold that recruits the body's own repair cells to fill focal knee cartilage defects; the single-stage outpatient procedure produces IKDC improvements of approximately 30 points with reoperation rates of 3–8%.
Severe knee osteoarthritis damages both the cartilage surface and the synovial membrane. For Kellgren–Lawrence grade III or IV patients considering replacement surgery, the dual injection protocol addresses both in one visit: ChondroFiller scaffolds cartilage repair whilst Arthrosamid buffers the synovial lining.
Patients treated with ChondroFiller show mean IKDC improvement of 32.4 points sustained at 36 months, with 70–85% achieving meaningful symptom relief at 3–5 years and reoperation rates of 3–8%.
Microfracture creates fibrocartilage deficient in glycosaminoglycans, the molecules that absorb joint compression; this tissue progressively fails from year two. ChondroFiller injection uses a collagen scaffold to avoid bone damage and sustain organised repair through years two to five.
